ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

XOMA XOMA Corporation

25.28
-1.42 (-5.32%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
XOMA Corporation NASDAQ:XOMA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.42 -5.32% 25.28 20.67 43.55 26.72 26.00 26.35 9,018 01:00:00

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

14/05/2024 12:30pm

GlobeNewswire Inc.


XOMA (NASDAQ:XOMA)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more XOMA Charts.

XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.

Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat taking place at 11:00 AM ET.  The presentation can be accessed at https://bit.ly/4aQ74Y8.

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA CorporationXOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com.

XOMA Investor Contact  XOMA Media Contact
Juliane SnowdenKathy Vincent
XOMA Corporation KV Consulting & Management
+1 646-438-9754  +1 310-403-8951
juliane.snowden@xoma.comkathy@kathyvincent.com

1 Year XOMA Chart

1 Year XOMA Chart

1 Month XOMA Chart

1 Month XOMA Chart

Your Recent History

Delayed Upgrade Clock